Diabetformin

Diabetformin may be available in the countries listed below.

Ingredient matches for Diabetformin

Metformin

Metformin is reported as an ingredient of Diabetformin in the following countries:

• Peru

International Drug Name Search

Uroacis

Uroacis may be available in the countries listed below.

Ingredient matches for Uroacis

Potassium Sodium Hydrogen Citrate

Potassium Sodium Hydrogen Citrate is reported as an ingredient of Uroacis in the following countries:

• Japan

International Drug Name Search

Tétrazépam Teva

Tétrazépam Teva may be available in the countries listed below.

Ingredient matches for Tétrazépam Teva

Tetrazepam

Tetrazepam is reported as an ingredient of Tétrazépam Teva in the following countries:

• France

International Drug Name Search

Vascam

Vascam may be available in the countries listed below.

Ingredient matches for Vascam

Amlodipine

Amlodipine besilate (a derivative of Amlodipine) is reported as an ingredient of Vascam in the following countries:

• Vietnam

International Drug Name Search

Omeprazol Valeant

Omeprazol Valeant may be available in the countries listed below.

Ingredient matches for Omeprazol Valeant

Omeprazole

Omeprazole is reported as an ingredient of Omeprazol Valeant in the following countries:

• Portugal

International Drug Name Search

Elfivir

Elfivir may be available in the countries listed below.

Ingredient matches for Elfivir

Nelfinavir

Nelfinavir is reported as an ingredient of Elfivir in the following countries:

• Peru

International Drug Name Search

DHA-Simvastatin

DHA-Simvastatin may be available in the countries listed below.

Ingredient matches for DHA-Simvastatin

Simvastatin

Simvastatin is reported as an ingredient of DHA-Simvastatin in the following countries:

• Singapore

International Drug Name Search

DDS Dental Wipes

Dosage Form: FOR ANIMAL USE ONLY

Active Ingredients

0.1% Chlorhexidine Gluconate

Directions

Gently wipe pet's teeth and gums with pad. Use additional pads as needed to clean entire mouth.

KEEP OUT OF REACH OF CHILDREN AND PETS TO AVOID UNINTENDED CONSUMPTION

Easy to Use

D.D.S. Dental Care for Dogs

Dental Wipes

Breath Control

Cleans Teeth and gums, freshens breath

90 PADS

Other Ingredients

Water, Glycerin, Polysorbate 80, Peppermint Flavor, Carmine Color.

DDS  dental wipes  cloth

Product Information Product Type OTC ANIMAL DRUG NDC Product Code (Source) 24730-412 Route of Administration DENTAL DEA Schedule

Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength CHLORHEXIDINE GLUCONATE (CHLORHEXIDINE) CHLORHEXIDINE GLUCONATE 0.55 g  in 103.6 g

Inactive Ingredients Ingredient Name Strength WATER   GLYCERIN   POLYSORBATE 80

Product Characteristics Color red Score      Shape Size Flavor PEPPERMINT Imprint Code Contains

Packaging # NDC Package Description Multilevel Packaging 1 24730-412-05 103.6 g In 1 JAR None

Marketing Information
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
unapproved drug other		01/01/2001

Labeler - United Pet Group (931135730)

Establishment
Name	Address	ID/FEI	Operations
JUNGLE LABORATORIES CORPORATION		032615270	manufacture

Revised: 04/2010United Pet Group

Adrenalina WZF

Adrenalina WZF may be available in the countries listed below.

Ingredient matches for Adrenalina WZF

Epinephrine

Epinephrine is reported as an ingredient of Adrenalina WZF in the following countries:

• Poland

International Drug Name Search

Maxiflam

Maxiflam may be available in the countries listed below.

Ingredient matches for Maxiflam

Naproxen

Naproxen sodium salt (a derivative of Naproxen) is reported as an ingredient of Maxiflam in the following countries:

• Peru

International Drug Name Search

Levohexal

Levohexal may be available in the countries listed below.

Ingredient matches for Levohexal

Carbidopa

Carbidopa monohydrate (a derivative of Carbidopa) is reported as an ingredient of Levohexal in the following countries:

• Australia

Levodopa

Levodopa is reported as an ingredient of Levohexal in the following countries:

• Australia

International Drug Name Search

Dexamethason acis

Dexamethason acis may be available in the countries listed below.

Ingredient matches for Dexamethason acis

Dexamethasone

Dexamethasone is reported as an ingredient of Dexamethason acis in the following countries:

• Germany

Dexamethasone 21-(disodium phosphate) (a derivative of Dexamethasone) is reported as an ingredient of Dexamethason acis in the following countries:

• Germany

International Drug Name Search

Opegan Hi

Opegan Hi may be available in the countries listed below.

Ingredient matches for Opegan Hi

Hyaluronic Acid

Hyaluronic Acid sodium salt (a derivative of Hyaluronic Acid) is reported as an ingredient of Opegan Hi in the following countries:

• Japan

International Drug Name Search

Neo-Recormon

Neo-Recormon may be available in the countries listed below.

Ingredient matches for Neo-Recormon

Epoetin Beta-Methoxy Polyethylene Glycol

Epoetin Beta is reported as an ingredient of Neo-Recormon in the following countries:

• Turkey

International Drug Name Search

Aminobenzoic Acid

In some countries, this medicine may only be approved for veterinary use.

Scheme

USP

ATC (Anatomical Therapeutic Chemical Classification)

D02BA01

CAS registry number (Chemical Abstracts Service)

0000150-13-0

Chemical Formula

C7-H7-N-O2

Molecular Weight

137

Therapeutic Category

Dermatological agent: Sunscreen

Chemical Name

Benzoic acid, amino-

Foreign Names

• Acidum aminobenzoicum (Latin)
• Aminobenzoesäure (German)
• Acide aminobenzoïque (French)

Generic Names

• Aminobenzoïque (acide) (OS: DCF)
• 4-Aminobenzoesäure (IS: IUPAC)
• Acidum 4-aminobenzoicum (IS)
• PAB (IS)
• PABA (IS: INCI)
• p-Aminobenzoesäure (IS)
• Vitamine Bx (IS)
• Vitamine H' (IS)
• 4-Aminobenzoic Acid (PH: Ph. Eur. 6)
• Acidum 4-aminobenzoicum (PH: Ph. Eur. 6)
• Acidum paraminobenzoicum (PH: Ph. Helv. 8)
• Aminobenzoic Acid (PH: USP 32, BP 2010)
• p-Aminobenzoic Acid (PH: USP 30)
• KPAB (IS)
• Potassium p-aminobenzoate (IS)
• Aminobenzoate Potassium (PH: USP 32)

Brand Names

• Eczema (Aminobenzoic Acid andCetrimide (veterinary use))
  Bomac, New Zealand



• Hachemina
  Medea, Spain



• Pabasun
  Dexo, France



• Paraminan
  Dexo, France



• Paraminol
  Franco-Indian, India



• Aflogol
  Sanitas, Chile



• Potaba
  Glenwood, Austria; Glenwood, Canada; Glenwood, United Kingdom; Glenwood, United States



• Potaba-Glenwood
  Glenwood, Germany

International Drug Name Search

Glossary

DCF	Dénomination Commune Française
IUPAC	International Union of Pure and Applied Chemistry
IS	Inofficial Synonym
OS	Official Synonym
PH	Pharmacopoeia Name
USP	Pharmacopoeia of the United States

Click for further information on drug naming conventions and International Nonproprietary Names.

Bercetina

Bercetina may be available in the countries listed below.

Ingredient matches for Bercetina

Flunarizine

Flunarizine dihydrochloride (a derivative of Flunarizine) is reported as an ingredient of Bercetina in the following countries:

• Argentina

International Drug Name Search

Cromopan

Cromopan may be available in the countries listed below.

Ingredient matches for Cromopan

Cromoglicic Acid

Cromoglicic Acid disodium salt (a derivative of Cromoglicic Acid) is reported as an ingredient of Cromopan in the following countries:

• Bangladesh

International Drug Name Search

Azitromycine PCH

Azitromycine PCH may be available in the countries listed below.

Ingredient matches for Azitromycine PCH

Azithromycin

Azithromycin is reported as an ingredient of Azitromycine PCH in the following countries:

• Netherlands

International Drug Name Search

PMS-Temazepam

PMS-Temazepam may be available in the countries listed below.

Ingredient matches for PMS-Temazepam

Temazepam

Temazepam is reported as an ingredient of PMS-Temazepam in the following countries:

• Canada

International Drug Name Search

Dyrex

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Dyrex

Atropine

Atropine is reported as an ingredient of Dyrex in the following countries:

• United States

Metrifonate

Metrifonate is reported as an ingredient of Dyrex in the following countries:

• United States

International Drug Name Search

Glukofen

Glukofen may be available in the countries listed below.

Ingredient matches for Glukofen

Metformin

Metformin hydrochloride (a derivative of Metformin) is reported as an ingredient of Glukofen in the following countries:

• Turkey

International Drug Name Search

Nitren Lich

Nitren Lich may be available in the countries listed below.

Ingredient matches for Nitren Lich

Nitrendipine

Nitrendipine is reported as an ingredient of Nitren Lich in the following countries:

• Germany

International Drug Name Search

Lamivox

Lamivox may be available in the countries listed below.

Ingredient matches for Lamivox

Lamivudine

Lamivudine is reported as an ingredient of Lamivox in the following countries:

• Ethiopia


• Peru

International Drug Name Search

Bieskadog

Bieskadog may be available in the countries listed below.

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Bieskadog

Framycetin

Framycetin sulfate (a derivative of Framycetin) is reported as an ingredient of Bieskadog in the following countries:

• France

Sulfaguanidine

Sulfaguanidine is reported as an ingredient of Bieskadog in the following countries:

• France

International Drug Name Search

Besonin Aqua

Besonin Aqua may be available in the countries listed below.

Ingredient matches for Besonin Aqua

Budesonide

Budesonide is reported as an ingredient of Besonin Aqua in the following countries:

• Taiwan

International Drug Name Search

Kanamycin

In some countries, this medicine may only be approved for veterinary use.

In the US, Kanamycin (kanamycin systemic) is a member of the drug class aminoglycosides and is used to treat Bacterial Infection, Peritonitis and Tuberculosis - Active.

US matches:

• Kanamycin


• Kanamycin Injection


• Kanamycin Sulfate

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

A07AA08,J01GB04,S01AA24

CAS registry number (Chemical Abstracts Service)

0000059-01-8

Chemical Formula

C18-H36-N4-O11

Molecular Weight

484

Therapeutic Category

Antibacterial: Aminoglycoside

Chemical Name

D-Streptamine, O-3-amino-3-deoxy-α-D-glucopyranosyl-(1-6)-O-[6-amino-6-deoxy-α-D-glucopyranosyl-(1-4)]-2-deoxy-

Foreign Names

• Kanamycinum (Latin)
• Kanamycin (German)
• Kanamycine (French)
• Kanamicina (Spanish)

Generic Names

• Kanamicina (OS: DCIT)
• Kanamycin (OS: BAN)
• Kanamycine (OS: DCF)
• Kanamycin A (IS)
• Kanamycin Sulphate (OS: BANM)
• Kanamycin Monosulphate (PH: Ph. Eur. 6)
• Kanamycin Sulfate (PH: USP 32, JP XIV)
• Kanamycin Sulphate (PH: BP 2010)
• Kanamycine (monosulfate de) (PH: Ph. Eur. 6)
• Kanamycini monosulfas (PH: Ph. Eur. 6)
• Kanamycinmonosulfat (PH: Ph. Eur. 6)

Brand Names

• Kancin
  Alembic, India



• Pan-Kanamycin
  Panpharma, Lithuania



• Ubrolexin (Kanamycin and Cefalexin (veterinary use))
  Boehringer Ingelheim Vetmedica, Austria



• A.N.B. Kanamycin Sulfacte
  ANB, Myanmar



• Bio-Kanamycin
  Biotech Laboratories, South Africa



• Canamicin Coulfat
  Batfarma, Georgia



• Cristalomicina
  Ivax, Argentina



• Dermaflogil (Kanamycin and Diflucortolone)
  Nuovo, Italy



• Kanacyn
  Continental, United Arab Emirates; Continental, Jordan; Continental, Lebanon; Continental, Luxembourg; Continental, Saudi Arabia; Continental, Sudan; Continental, Syria



• Kanamastine (Kanamycin and Spiramycin (veterinary use))
  Biokema, Switzerland



• Kanamicinã Sulfat
  Antibiotice, Romania



• Kanamycin Capsules Meiji
  Meiji, Indonesia; Meiji, Thailand



• Kanamycin Meiji
  Meiji, Hong Kong; Meiji, Taiwan



• Kanamycin Ogris (veterinary use)
  Ogris, Austria



• Kanamycin Sanbe
  Sanbe, Indonesia



• Kanamycin Sulfate Injection Meiji
  Meiji, Thailand



• Kanamycin Sulfate
  APP, United States; Meiji Seika Kaisha, Japan



• Kanamycin Sulphate Meiji
  Meiji, Indonesia



• Kanamycin Syrup Meiji
  Meiji, Indonesia



• Kanamycin Virbac (veterinary use)
  Virbac, Austria



• Kanamycin
  Biochem, India; Meiji Seika Kaisha, Japan



• Kanamycine (veterinary use)
  Alfasan, Netherlands; Kela, Belgium



• Kanamycin-POS
  Ursapharm, Czech Republic; Ursapharm, Germany



• Kanamyn (veterinary use)
  Virbac, South Africa



• Kanamysel (veterinary use)
  Selecta, Germany



• Kanamytrex
  Alcon, Germany



• Kanarco
  Armoxindo, Indonesia



• Kanaspray (veterinary use)
  Intervet, Italy



• Kana-Stulln
  Stulln, Germany



• Kanaxin (veterinary use)
  AFI, Italy



• Kancin
  Alembic, India; Atlantic, Singapore



• Kan-Ophtal
  Winzer, Germany



• Kantrex
  Bristol-Myers Squibb, Kenya; Bristol-Myers Squibb, Tanzania; Bristol-Myers Squibb, Uganda; Bristol-Myers Squibb, Venezuela



• Kantrim (veterinary use)
  Fort Dodge Animale Health, United States



• Keimicina
  Zambon, Italy



• Neo-Kanapront (veterinary use)
  VAAS, Italy



• Pan-Kanamycin
  Panpharma, Latvia



• Pan-Kanamycine
  Panpharma, Romania



• Ubrolexin (Kanamycin and Cefalexin (veterinary use))
  Boehringer Ingelheim Santé Animale, France



• Vanakan (veterinary use)
  Vana, Austria

International Drug Name Search

Glossary

BAN	British Approved Name
BANM	British Approved Name (Modified)
DCF	Dénomination Commune Française
DCIT	Denominazione Comune Italiana
IS	Inofficial Synonym
OS	Official Synonym
PH	Pharmacopoeia Name
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)

Click for further information on drug naming conventions and International Nonproprietary Names.

Calcium Dobesilate

Calcium dobesilate may be available in the countries listed below.

Ingredient matches for Calcium dobesilate

Calcium Dobesilate

Calcium Dobesilate is reported as an ingredient of Calcium dobesilate in the following countries:

• Poland

Calcium Dobesilate monohydrate (a derivative of Calcium Dobesilate) is reported as an ingredient of Calcium dobesilate in the following countries:

• Poland

International Drug Name Search

Dolofar

Dolofar may be available in the countries listed below.

Ingredient matches for Dolofar

Ketoprofen

Ketoprofen is reported as an ingredient of Dolofar in the following countries:

• Chile

International Drug Name Search

Budesonide A

Budesonide A may be available in the countries listed below.

Ingredient matches for Budesonide A

Budesonide

Budesonide is reported as an ingredient of Budesonide A in the following countries:

• Netherlands

International Drug Name Search

Amiobutols

Amiobutols may be available in the countries listed below.

Ingredient matches for Amiobutols

Ethambutol

Ethambutol dihydrochloride (a derivative of Ethambutol) is reported as an ingredient of Amiobutols in the following countries:

• Latvia

International Drug Name Search

Lonnoten

Lonnoten may be available in the countries listed below.

Ingredient matches for Lonnoten

Minoxidil

Minoxidil is reported as an ingredient of Lonnoten in the following countries:

• Luxembourg


• Netherlands

International Drug Name Search

Selegilin-Teva

Selegilin-Teva may be available in the countries listed below.

Ingredient matches for Selegilin-Teva

Selegiline

Selegiline hydrochloride (a derivative of Selegiline) is reported as an ingredient of Selegilin-Teva in the following countries:

• Germany

International Drug Name Search

Servicef

Servicef may be available in the countries listed below.

Ingredient matches for Servicef

Cefalexin

Cefalexin monohydrate (a derivative of Cefalexin) is reported as an ingredient of Servicef in the following countries:

• Mexico

International Drug Name Search

Baktar

Baktar may be available in the countries listed below.

Ingredient matches for Baktar

Sulfamethoxazole

Sulfamethoxazole is reported as an ingredient of Baktar in the following countries:

• Japan


• Taiwan

Trimethoprim

Trimethoprim is reported as an ingredient of Baktar in the following countries:

• Japan


• Taiwan

International Drug Name Search

Hair-Treat

Hair-Treat may be available in the countries listed below.

Ingredient matches for Hair-Treat

Minoxidil

Minoxidil is reported as an ingredient of Hair-Treat in the following countries:

• Israel

International Drug Name Search

Dinidol

Dinidol may be available in the countries listed below.

Ingredient matches for Dinidol

Difenidol

Difenidol hydrochloride (a derivative of Difenidol) is reported as an ingredient of Dinidol in the following countries:

• Taiwan

International Drug Name Search

Panoxyl

In the US, Panoxyl (benzoyl peroxide topical) is a member of the drug class topical acne agents and is used to treat Acne and Perioral Dermatitis.

US matches:

• PanOxyl Bar


• PanOxyl


• PanOxyl Maximum Strength Foaming Acne Wash


• Panoxyl 10


• Panoxyl 5


• Panoxyl Aqua Gel


• Panoxyl Soap

UK matches:

• PanOxyl 10 Aquagel 10%w/w Gel (SPC)
• PanOxyl 5 Aquagel 5%w/w Gel (SPC)
• PanOxyl 5 Cream (SPC)
• Panoxyl Acne Gel 5, 10 (SPC)
• Panoxyl Aquagel 2.5, 5, 10 (SPC)
• PanOxyl Wash 10% (SPC)

Ingredient matches for Panoxyl

Benzoyl Peroxide

Benzoyl Peroxide is reported as an ingredient of Panoxyl in the following countries:

• Australia


• Bahrain


• Canada


• Colombia


• Costa Rica


• Egypt


• El Salvador


• France


• Germany


• Guatemala


• Honduras


• Hong Kong


• Iceland


• Iran


• Ireland


• Israel


• Italy


• Jordan


• Kenya


• Kuwait


• Lebanon


• Luxembourg


• Malta


• New Zealand


• Nicaragua


• Norway


• Panama


• Peru


• Portugal


• Qatar


• Saudi Arabia


• Singapore


• Syria


• Taiwan


• Tunisia


• United Arab Emirates


• United Kingdom


• United States


• Yemen


• Zimbabwe

International Drug Name Search

Glossary

SPC	Summary of Product Characteristics (UK)

Click for further information on drug naming conventions and International Nonproprietary Names.

Seal and Heal

Seal and Heal may be available in the countries listed below.

Ingredient matches for Seal and Heal

Salicylic Acid

Salicylic Acid is reported as an ingredient of Seal and Heal in the following countries:

• Poland

International Drug Name Search

Ciproflomed

Ciproflomed may be available in the countries listed below.

Ingredient matches for Ciproflomed

Ciprofloxacin

Ciprofloxacin is reported as an ingredient of Ciproflomed in the following countries:

• Belgium

International Drug Name Search

Zopiban

Zopiban may be available in the countries listed below.

Ingredient matches for Zopiban

Eszopiclone

Zopiclone is reported as an ingredient of Zopiban in the following countries:

• Japan

International Drug Name Search

Mopac

Mopac may be available in the countries listed below.

Ingredient matches for Mopac

Mometasone

Mometasone 17-(2-furoate) (a derivative of Mometasone) is reported as an ingredient of Mopac in the following countries:

• Ecuador

International Drug Name Search

Alivium

Alivium may be available in the countries listed below.

Ingredient matches for Alivium

Ibuprofen

Ibuprofen is reported as an ingredient of Alivium in the following countries:

• Peru

International Drug Name Search

Equiworld Fly

Equiworld Fly may be available in the countries listed below.

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Equiworld Fly

Cypermethrin

Cypermethrin is reported as an ingredient of Equiworld Fly in the following countries:

• South Africa

Piperonyl Butoxide

Piperonyl Butoxide is reported as an ingredient of Equiworld Fly in the following countries:

• South Africa

International Drug Name Search

Traumasept

Traumasept may be available in the countries listed below.

Ingredient matches for Traumasept

Povidone Iodine

Povidone-Iodine is reported as an ingredient of Traumasept in the following countries:

• Germany


• Latvia

International Drug Name Search

Curinflam

Curinflam may be available in the countries listed below.

Ingredient matches for Curinflam

Diclofenac

Diclofenac sodium salt (a derivative of Diclofenac) is reported as an ingredient of Curinflam in the following countries:

• Argentina


• Dominican Republic

International Drug Name Search

Betaclopramide

Betaclopramide may be available in the countries listed below.

Ingredient matches for Betaclopramide

Metoclopramide

Metoclopramide hydrochloride (a derivative of Metoclopramide) is reported as an ingredient of Betaclopramide in the following countries:

• South Africa

International Drug Name Search

Slow Deralin

Slow Deralin may be available in the countries listed below.

Ingredient matches for Slow Deralin

Propranolol

Propranolol hydrochloride (a derivative of Propranolol) is reported as an ingredient of Slow Deralin in the following countries:

• Israel

International Drug Name Search

Rifun

Rifun may be available in the countries listed below.

Ingredient matches for Rifun

Pantoprazole

Pantoprazole sodium (a derivative of Pantoprazole) is reported as an ingredient of Rifun in the following countries:

• Germany

International Drug Name Search

Cytarabine Hospira

Cytarabine Hospira may be available in the countries listed below.

Ingredient matches for Cytarabine Hospira

Cytarabine

Cytarabine is reported as an ingredient of Cytarabine Hospira in the following countries:

• Belgium


• Netherlands

International Drug Name Search

Claritromicina Tarbis

Claritromicina Tarbis may be available in the countries listed below.

Ingredient matches for Claritromicina Tarbis

Clarithromycin

Clarithromycin is reported as an ingredient of Claritromicina Tarbis in the following countries:

• Spain

International Drug Name Search

Rhophylac

Dosage Form: injection
FULL PRESCRIBING INFORMATION

Rhophylac®

Rh0(D) Immune Globulin Intravenous (Human)

WARNING: INTRAVASCULAR HEMOLYSIS IN ITP

This warning does not apply to Rh0(D)-negative patients treated for the suppression of Rh isoimmunization.

• Intravascular hemolysis leading to death has been reported in Rh0(D)-positive patients treated for immune thrombocytopenic purpura (ITP) with Rh0(D) Immune Globulin Intravenous (Human) products.1


• Intravascular hemolysis can lead to clinically compromising anemia and multi-system organ failure including acute respiratory distress syndrome (ARDS).


• Serious complications, including severe anemia, acute renal insufficiency, renal failure, and disseminated intravascular coagulation (DIC), have also been reported.


• Closely monitor patients treated for ITP with Rhophylac in a healthcare setting for at least 8 hours after administration. Perform a dipstick urinalysis at baseline, 2 hours and 4 hours after administration, and prior to the end of the monitoring period. Alert patients to, and monitor them for, the signs and symptoms of intravascular hemolysis, including back pain, shaking chills, fever, and discolored urine or hematuria. Absence of these signs and/or symptoms within 8 hours does not indicate IVH cannot occur subsequently. If signs and/or symptoms of intravascular hemolysis are present or suspected after Rhophylac administration, perform post-treatment laboratory tests, including plasma hemoglobin, haptoglobin, LDH, and plasma bilirubin (direct and indirect).

Indications and Usage for Rhophylac

Rhophylac is an Rh0(D) Immune Globulin Intravenous (Human) (anti-D) product that is indicated for the suppression of Rh isoimmunization in non-sensitized Rh0(D)-negative patients and for the treatment of immune thrombocytopenic purpura (ITP) in Rh0(D)-positive patients.

Suppression of Rh Isoimmunization

Pregnancy and Obstetric Conditions

Rhophylac is indicated for suppression of rhesus (Rh) isoimmunization in non-sensitized Rh0(D)-negative women with an Rh-incompatible pregnancy, including:

• Routine antepartum and postpartum Rh prophylaxis


• Rh prophylaxis in cases of:
  

  –

  
  

  Obstetric complications (e.g., miscarriage, abortion, threatened abortion, ectopic pregnancy or hydatidiform mole, transplacental hemorrhage resulting from antepartum hemorrhage)

  
  

  –

  
  

  Invasive procedures during pregnancy (e.g., amniocentesis, chorionic biopsy) or obstetric manipulative procedures (e.g., external version, abdominal trauma)

  
  

An Rh-incompatible pregnancy is assumed if the fetus/baby is either Rh0(D)-positive or Rh0(D)-unknown or if the father is either Rh0(D)-positive or Rh0(D)-unknown.

Incompatible Transfusions

Rhophylac is indicated for the suppression of Rh isoimmunization in Rh0(D)-negative individuals transfused with Rh0(D)-positive red blood cells (RBCs) or blood components containing Rh0(D)-positive RBCs.

Treatment can be given without a preceding exchange transfusion when the transfused blood represents less than 20% of the total circulating RBCs. If the volume exceeds 20%, an exchange transfusion should be considered prior to administering Rhophylac.

ITP

Rhophylac is indicated in Rh0(D)-positive, non-splenectomized adult patients with chronic ITP to raise platelet counts.

Rhophylac Dosage and Administration

As with all blood products, patients should be observed for at least 20 minutes following administration of Rhophylac.

Preparation and Handling

• 
  

   Rhophylac is a clear or slightly opalescent, colorless to pale yellow solution. Inspect Rhophylac visually for particulate matter and discoloration prior to administration. Do not use if the solution is cloudy or contains particulates.

  
  


• 
  

   Prior to intravenous use, ensure that the needle-free intravenous administration system is compatible with the tip of the Rhophylac glass syringe.

  
  


• 
  

   Do not freeze.

  
  


• 
  

   Bring Rhophylac to room temperature before use.

  
  


• 
  

   Rhophylac is for single use only. Dispose of any unused product or waste material in accordance with local requirements.

  
  

Suppression of Rh Isoimmunization

Rhophylac should be administered by intravenous or intramuscular injection. If large doses (greater than 5 mL) are required and intramuscular injection is chosen, it is advisable to administer Rhophylac in divided doses at different sites.

Table 1 provides dosing guidelines based on the condition being treated.

Table 1: Dosing Guidelines for Suppression of Rh Isoimmunization

Indication	Timing of Administration	Dose* (Administer by Intravenous or Intramuscular Injection)
IU, international units; mcg, micrograms.
* A 1500 IU (300 mcg) dose of Rhophylac will suppress the immunizing potential of ≥15 mL of Rh0(D)-positive RBCs.2 † The dose of Rhophylac must be increased if the patient is exposed to >15 mL of Rh0(D)-positive RBCs; in this case, follow the dosing guidelines for excessive fetomaternal hemorrhage.
Rh-incompatible pregnancy
Routine antepartum prophylaxis	At Week 28-30 of gestation	1500 IU (300 mcg)
Postpartum prophylaxis (required only if the newborn is Rh0(D)-positive)	Within 72 hours of birth	1500 IU (300 mcg)†
Obstetric complications (e.g., miscarriage, abortion, threatened abortion, ectopic pregnancy or hydatidiform mole, transplacental hemorrhage resulting from antepartum hemorrhage)	Within 72 hours of complication	1500 IU (300 mcg)†
Invasive procedures during pregnancy (e.g., amniocentesis, chorionic biopsy) or obstetric manipulative procedures (e.g., external version, abdominal trauma)	Within 72 hours of procedure	1500 IU (300 mcg)†
Excessive fetomaternal hemorrhage (>15 mL)	Within 72 hours of complication	1500 IU (300 mcg) plus: 100 IU (20 mcg) per mL fetal RBCs in excess of 15 mL if excess transplacental bleeding is quantified or An additional 1500 IU (300 mcg) dose if excess transplacental bleeding cannot be quantified
Incompatible transfusions	Within 72 hours of exposure	100 IU (20 mcg) per 2 mL transfused blood or per 1 mL erythrocyte concentrate

ITP

For treatment of ITP, ADMINISTER Rhophylac BY THE INTRAVENOUS ROUTE ONLY (see Preparation and Handling [2.1]). Do not administer intramuscularly.

A 250 IU (50 mcg) per kg body weight dose of Rhophylac is recommended for patients with ITP. The following formula can be used to calculate the recommended amount of Rhophylac to administer:

Dose (IU) × body weight (kg) = Total IU / 1500 IU per syringe = Number of syringes

Rhophylac should be administered at a rate of 2 mL per 15 to 60 seconds.

Dosage Forms and Strengths

1500 IU (300 mcg) per 2 mL prefilled, ready-to-use, glass syringe

Contraindications

• Rhophylac is contraindicated in patients who have had an anaphylactic or severe systemic reaction to the administration of human immune globulin.


• Rhophylac is contraindicated in IgA-deficient patients with antibodies to IgA and a history of hypersensitivity.

Warnings and Precautions

Both Indications

 5.1.1 Hypersensitivity

 Severe hypersensitivity reactions may occur. If symptoms of allergic or early signs of hypersensitivity reactions (including generalized urticaria, tightness of the chest, wheezing, hypotension, and anaphylaxis) occur, discontinue Rhophylac administration immediately and institute appropriate treatment. Medications such as epinephrine should be available for immediate treatment of acute hypersensitivity reactions.

 Rhophylac contains trace amounts of IgA (less than 5 mcg/mL) (see Description [11]). Patients with known antibodies to IgA have a greater risk of developing potentially severe hypersensitivity and anaphylactic reactions. Rhophylac is contraindicated in patients with antibodies against IgA and a history of hypersensitivity reactions (see Contraindications [4]).

5.1.2 Interference with Laboratory Tests

The administration of Rh0(D) immune globulin may affect the results of blood typing, the antibody screening test, and the direct antiglobulin (Coombs') test. Antepartum administration of Rh0(D) immune globulin to the mother can also affect these tests in the newborn infant.

Rhophylac can contain antibodies to other Rh antigens (e.g., anti-C antibodies), which might be detected by sensitive serological tests following administration.

5.1.3 Transmissible Infectious Agents

Because Rhophylac is made from human blood, it may carry a risk of transmitting infectious agents, e.g., viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. The risk of infectious agent transmission has been reduced by screening plasma donors for prior exposure to certain viruses, testing for the presence of certain current virus infections, and including virus inactivation/removal steps in the manufacturing process for Rhophylac.

Report any infections thought to be possibly transmitted by Rhophylac to CSL Behring Pharmacovigilance at 1-866-915-6958.

Suppression of Rh Isoimmunization

5.2.1 Postpartum Use Following an Rh-incompatible Pregnancy

Administer Rhophylac to the mother only. Do not administer to the newborn infant (see Pediatric Use [8.4]).

ITP

 5.3.1 Intravascular Hemolysis

 Intravascular hemolysis has occurred in a clinical study with Rhophylac. All cases resolved completely. However, as reported in the literature, some Rh0(D)-positive patients treated with Rh0(D) Immune Globulin Intravenous (Human) for ITP developed clinically compromising anemia, acute renal insufficiency, and, very rarely, disseminated intravascular coagulation (DIC) and death.1 Note: This warning does not apply to Rh0(D)-negative patients treated for the suppression of Rh isoimmunization.

 Closely monitor patients in a healthcare setting for at least 8 hours after administration of Rhophylac. Perform a dipstick urinalysis at baseline, 2 hours and 4 hours after administration, and prior to the end of the monitoring period.

 Alert patients to, and monitor them for, the signs and symptoms of intravascular hemolysis, including back pain, shaking chills, fever, and discolored urine or hematuria. Absence of these signs and/or symptoms of intravascular hemolysis within 8 hours do not indicate intravascular hemolysis cannot occur subsequently.

 If signs and/or symptoms of intravascular hemolysis are present or suspected after Rhophylac administration, perform post-treatment laboratory tests, including plasma hemoglobin, haptoglobin, LDH, and plasma bilirubin (direct and indirect). DIC may be difficult to detect in the ITP population; the diagnosis is dependent mainly on laboratory testing.

If patients who develop hemolysis with clinically compromising anemia after receiving Rhophylac are to be transfused, Rh0(D)-negative packed RBCs should be used to avoid exacerbating ongoing hemolysis.

5.3.2 Pre-existing Anemia

The safety of Rhophylac in the treatment of ITP has not been established in patients with pre-existing anemia. The physician must weigh the benefits of Rhophylac against the potential risk of increasing the severity of the anemia.

Adverse Reactions

The most serious adverse reactions in patients receiving Rh0(D) Immune Globulin Intravenous (Human) have been observed in the treatment of ITP and include intravascular hemolysis, clinically compromising anemia, acute renal insufficiency, and, very rarely, DIC and death (see Boxed Warning, Warnings and Precautions [5.3.1]).1

The most common adverse reactions observed in the use of Rhophylac for suppression of Rh isoimmunization (≥0.5% of subjects) are nausea, dizziness, headache, injection-site pain, and malaise.

The most common adverse reactions observed in the treatment of ITP (>14% of subjects) are chills, pyrexia/increased body temperature, and headache. Mild hemolysis (manifested by an increase in bilirubin, a decrease in hemoglobin, or a decrease in haptoglobin) was also observed.

Clinical Studies Experience

Because clinical studies are conducted under different protocols and widely varying conditions, adverse reaction rates observed cannot be directly compared to rates in other clinical trials and may not reflect the rates observed in practice.

Suppression of Rh Isoimmunization

In two clinical studies, 447 Rh0(D)-negative pregnant women received either an intravenous or intramuscular injection of Rhophylac 1500 IU (300 mcg) at Week 28 of gestation. A second 1500 IU (300 mcg) dose was administered to 267 (9 in Study 1 and 258 in Study 2) of these women within 72 hours of the birth of an Rh0(D)-positive baby. In addition, 30 women in Study 2 received at least one extra antepartum 1500 IU (300 mcg) dose due to obstetric complications (see Clinical Studies [14.1]).

The most common adverse reactions in study subjects were nausea (0.7%), dizziness (0.5%), headache (0.5%), injection-site pain (0.5%), and malaise (0.5%). A laboratory finding of a transient positive anti-C antibody test was observed in 0.9% of subjects.

ITP

In a clinical study, 98 Rh0(D)-positive adult subjects with chronic ITP received an intravenous dose of Rhophylac 250 IU (50 mcg) per kg body weight (see Clinical Studies [14.2]). Premedication to alleviate infusion-related side effects was not used except in a single subject who received acetaminophen and diphenhydramine.

Eighty-four (85.7%) subjects experienced 392 treatment-emergent adverse events (TEAEs). Sixty-nine (70.4%) subjects had 186 drug-related TEAEs (defined as TEAEs with a probable, possible, definite, or unknown relationship to the study drug). Within 24 hours of dosing, 73 (74.5%) subjects experienced 183 TEAEs, and 66 (67%) subjects experienced 156 drug-related TEAEs.

Mild hemolysis (manifested as an increase in bilirubin, a decrease in hemoglobin, or a decrease in haptoglobin) was observed. An increase in blood bilirubin was seen in 21% of subjects. The median decrease in hemoglobin was greatest (0.8 g/dL) at Day 6 and Day 8 following administration of Rhophylac.

Table 2 shows the most common TEAEs observed in the clinical study.

Table 2: Most Common Treatment-Emergent Adverse Events (TEAEs) in Subjects with ITP

TEAE	Number of Subjects (%) With a TEAE n=98	Number of Subjects (%) With a Drug-Related TEAE* n=98
* Defined as TEAEs with a possible, probable, definite, or unknown relationship to the study drug.
Chills	34 (34.7%)	34 (34.7%)
Pyrexia/ Increased body temperature	32 (32.6%)	30 (30.6%)
Increased blood bilirubin	21 (21.4%)	21 (21.4%)
Headache	14 (14.3%)	11 (11.2%)

Serious adverse events (SAEs) were reported in 10 (10.2%) subjects. SAEs considered to be drug-related were intravascular hemolytic reaction (hypotension, nausea, chills and headache, and a decrease in haptoglobin and hemoglobin) in two subjects; headache, dizziness, nausea, pallor, shivering, and weakness requiring hospitalization in one subject; and an increase in blood pressure and severe headache in one subject. All four subjects recovered completely.

Postmarketing Experience

Because postmarketing adverse reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to product exposure. The following adverse reactions have been identified during post-approval use of Rhophylac:

Suppression of Rh Isoimmunization

Hypersensitivity reactions, including rare cases of anaphylactic shock or anaphylactoid reactions, headache, dizziness, vertigo, hypotension, tachycardia, dyspnea, nausea, vomiting, rash, erythema, pruritus, chills, pyrexia, malaise, diarrhea and back pain have been reported. Transient injection-site irritation and pain have been observed following intramuscular administration.

ITP

Transient hemoglobinuria has been reported in a patient being treated with Rhophylac for ITP.

Drug Interactions

Live Virus Vaccines

Passive transfer of antibodies may transiently impair the immune response to live attenuated virus vaccines such as measles, mumps, rubella, and varicella (see Patient Counseling Information [17.1]).

USE IN SPECIFIC POPULATIONS

Pregnancy

Pregnancy Category C. Animal reproduction studies have not been conducted with Rhophylac.

Suppression of Rh Isoimmunization

The available evidence suggests that Rhophylac does not harm the fetus or affect future pregnancies or reproduction capacity when given to pregnant Rh0(D)-negative women for suppression of Rh isoimmunization.3

ITP

Rhophylac has not been evaluated in pregnant women with ITP.

Nursing Mothers

Suppression of Rh Isoimmunization

Rhophylac is used in nursing mothers for the suppression of Rh isoimmunization. No undesirable effects on a nursing infant are expected during breastfeeding.

ITP

Rhophylac has not been evaluated in nursing mothers with ITP.

Pediatric Use

Suppression of Rh Isoimmunization in Incompatible Transfusions

The safety and effectiveness of Rhophylac have not been established in pediatric subjects being treated for an incompatible transfusion. The physician should weigh the potential risks against the benefits of Rhophylac, particularly in girls whose later pregnancies may be affected if Rh isoimmunization occurs.

Geriatric Use

Suppression of Rh Isoimmunization in Incompatible Transfusions

Rhophylac has not been evaluated for treating incompatible transfusions in subjects 65 years of age and older.

ITP

Of the 98 subjects evaluated in the clinical study of Rhophylac for treatment of ITP (see Clinical Studies [14.2]), 19% were 65 years of age and older. No overall differences in effectiveness or safety were observed between these subjects and younger subjects.

Overdosage

There are no reports of known overdoses in patients being treated for suppression of Rh isoimmunization or ITP. Patients with incompatible transfusion or ITP who receive an overdose of Rh0(D) immune globulin should be monitored because of the potential risk for hemolysis.

Rhophylac Description

Rhophylac is a sterile Rh0(D) Immune Globulin Intravenous (Human) (anti-D) solution in a ready-to-use prefilled glass syringe for intravenous or intramuscular injection. One syringe contains at least 1500 IU (300 mcg) of IgG antibodies to Rh0(D) in a 2 mL solution, sufficient to suppress the immune response to at least 15 mL of Rh-positive RBCs.1 The product potency is expressed in IUs by comparison to the World Health Organization (WHO) standard, which is also the US and the European Pharmacopoeia standard.

Plasma is obtained from healthy Rh0(D)-negative donors who have been immunized with Rh0(D)-positive RBCs. The donors are screened carefully to reduce the risk of receiving donations containing blood-borne pathogens. Each plasma donation used in the manufacture of Rhophylac is tested for the presence of HBV surface antigen (HBsAg), HIV-1/2, and HCV antibodies. In addition, plasma used in the manufacture of Rhophylac is tested by FDA-licensed Nucleic Acid Testing (NAT) for HIV and HCV and found to be negative. An investigational NAT for HBV is also performed on all source plasma used and found to be negative; however, the significance of a negative result has not been established. The source plasma is also tested by NAT for hepatitis A virus (HAV) and B19 virus (B19V).

Rhophylac is produced by an ion-exchange chromatography isolation procedure4, using pooled plasma obtained by plasmapheresis of immunized Rh0(D)-negative US donors. The manufacturing process includes a solvent/detergent treatment step (using tri-n-butyl phosphate and Triton™ X-100) that is effective in inactivating enveloped viruses such as HIV, HCV, and HBV.5,6 Rhophylac is filtered using a Planova® 15 nanometer (nm) virus filter that has been validated to be effective in removing both enveloped and non-enveloped viruses. Table 3 presents viral clearance and inactivation data from validation studies, expressed as the mean log10 reduction factor (LRF).

Table 3: Virus Inactivation and Removal in Rhophylac

	HIV	PRV	BVDV	MVM
HIV, a model for HIV-1 and HIV-2; PRV, pseudorabies virus, a model for large, enveloped DNA viruses (e.g., herpes virus); BVDV, bovine viral diarrhea virus, a model for HCV and West Nile virus; MVM, minute virus of mice, a model for B19V and other small, non-enveloped DNA viruses.
Virus property
Genome	RNA	DNA	RNA	DNA
Envelope	Yes	Yes	Yes	No
Size (nm)	80-100	120-200	40-70	18-24
Manufacturing step	Mean LRF
Solvent/detergent treatment	≥6.0	≥5.6	≥5.4	Not tested
Chromatographic process steps	4.5	≥3.9	1.6	≥2.6
Virus filtration	≥6.3	≥5.6	≥5.5	3.4
Overall reduction (log10 units)	≥16.8	≥15.1	≥12.5	≥6.0

Rhophylac contains a maximum of 30 mg/mL of human plasma proteins, 10 mg/mL of which is human albumin added as a stabilizer. Prior to the addition of the stabilizer, Rhophylac has a purity greater than 95% IgG. Rhophylac contains less than 5 mcg/mL of IgA, which is the limit of detection. Additional excipients are approximately 20 mg/mL of glycine and up to 0.25 M of sodium chloride. Rhophylac contains no preservative. Human albumin is manufactured from pooled plasma of US donors by cold ethanol fractionation, followed by pasteurization.

Rhophylac - Clinical Pharmacology

Mechanism of Action

Suppression of Rh Isoimmunization

The mechanism by which Rh0(D) immune globulin suppresses immunization to Rh0(D)-positive RBCs is not completely known.

In a clinical study of Rh0(D)-negative healthy male volunteers, both the intravenous and intramuscular administration of a 1500 IU (300 mcg) dose of Rhophylac 24 hours after injection of 15 mL of Rh0(D)-positive RBCs resulted in an effective clearance of Rh0(D)-positive RBCs. On average, 99% of injected RBCs were cleared within 12 hours following intravenous administration and within 144 hours following intramuscular administration.

ITP

Rhophylac has been shown to increase platelet counts and to reduce bleeding in non-splenectomized Rh0(D)-positive subjects with chronic ITP. The mechanism of action is thought to involve the formation of Rh0(D) immune globulin RBC complexes, which are preferentially removed by the reticuloendothelial system, particularly the spleen. This results in Fc receptor blockade, thus sparing antibody-coated platelets.7

Pharmacokinetics

Suppression of Rh Isoimmunization

In a clinical study comparing the pharmacokinetics of intravenous versus intramuscular administration, 15 Rh0(D)-negative pregnant women received a single 1500 IU (300 mcg) dose of Rhophylac at Week 28 of gestation.8

Following intravenous administration, peak serum levels of Rh0(D) immune globulin ranged from 62 to 84 ng/mL after 1 day (i.e., the time the first blood sample was taken following the antepartum dose). Mean systemic clearance was 0.20 ± 0.03 mL/min, and half-life was 16 ± 4 days.

Following intramuscular administration, peak serum levels ranged from 7 to 46 ng/mL and were achieved between 2 and 7 days. Mean apparent clearance was 0.29 ± 0.12 mL/min, and half-life was 18 ± 5 days. The absolute bioavailability of Rhophylac was 69%.

Regardless of the route of administration, Rh0(D) immune globulin titers were detected in all women up to at least 9 weeks following administration of Rhophylac.

ITP

Pharmacokinetic studies with Rhophylac were not performed in Rh0(D)-positive subjects with ITP. Rh0(D) immune globulin binds rapidly to Rh0(D)-positive erythrocytes.9

Clinical Studies

Suppression of Rh Isoimmunization

In two clinical studies, 447 Rh0(D)-negative pregnant women received a 1500 IU (300 mcg) dose of Rhophylac during Week 28 of gestation. The women who gave birth to an Rh0(D)-positive baby received a second 1500 IU (300 mcg) dose within 72 hours of birth.

• Study 1 (Pharmacokinetic Study) – Eight of the women who participated in the pharmacokinetic study (see Clinical Pharmacology [12.3]) gave birth to an Rh0(D)-positive baby and received the postpartum dose of 1500 IU (300 mcg) of Rhophylac.8 Antibody tests performed 6 to 8 months later were negative for all women. This suggests that no Rh0(D) immunization occurred.


• Study 2 (Pivotal Study) – In an open-label, single-arm clinical study at 22 centers in the US and United Kingdom, 432 pregnant women received the antepartum dose of 1500 IU (300 mcg) of Rhophylac either as an intravenous or intramuscular injection (two randomized groups of 216 women each).10 Subjects received an additional 1500 IU (300 mcg) dose if an obstetric complication occurred between the routine antepartum dose and birth or if extensive fetomaternal hemorrhage was measured after birth. Of the 270 women who gave birth to an Rh0(D)-positive baby, 248 women were evaluated for Rh0(D) immunization 6 to 11.5 months postpartum. None of these women developed antibodies against the Rh0(D) antigen.

ITP

In an open-label, single-arm, multicenter study, 98 Rh0(D)-positive adult subjects with chronic ITP and a platelet count of 30 × 109/L or less were treated with Rhophylac. Subjects received a single intravenous dose of 250 IU (50 mcg) per kg body weight.

The primary efficacy endpoint was the response rate defined as achieving a platelet count of ≥30 × 109/L as well as an increase of >20 × 109/L within 15 days after treatment with Rhophylac. Secondary efficacy endpoints included the response rate defined as an increase in platelet counts to ≥50 × 109/L within 15 days after treatment and, in subjects who had bleeding at baseline, the regression of hemorrhage defined as any decrease from baseline in the severity of overall bleeding status.

Table 4 presents the primary response rates for the intent-to-treat (ITT) and per-protocol (PP) populations.

Table 4: Primary Response Rates (ITT and PP Populations)

Analysis Population	No. Subjects	No. Responders	Primary Response Rate at Day 15
			% Responders	95% Confidence Interval (CI)
ITT	98	65	66.3%	56.5%, 74.9%
PP	92	62	67.4%	57.3%, 76.1%

The primary efficacy response rate (ITT population) demonstrated a clinically relevant response to treatment, i.e., the lower bound of the 95% confidence interval (CI) was greater than the predefined response rate of 50%. The median time to platelet response was 3 days, and the median duration of platelet response was 22 days.

Table 5 presents the response rates by baseline platelet count for subjects in the ITT population.

Table 5: Response Rates By Baseline Platelet Count (ITT Population)

		Response Rates at Day 15
Baseline Platelet count (× 109/L)	Total No. Subjects	No. (%) Subjects Achieving a Platelet Count of ≥30 × 109/L and an Increase of >20 × 109/L	No. (%) Subjects With an Increase in Platelet Counts to ≥50 × 109/L
* Reflects subjects with a platelet count of ≤30 × 109/L at screening but >30 × 109/L immediately before treatment.
≤10	38	15 (39.5)	10 (26.3)
>10 to 20	28	22 (78.6)	17 (60.7)
>20 to 30	27	24 (88.9)	22 (81.5)
>30*	5	4 (80.0)	5 (100.0)
Overall (all subjects)	98	65 (66.3)	54 (55.1)

During the study, an overall regression of hemorrhage was seen in 44 (88%, 95% CI: 76% to 94%) of the 50 subjects with bleeding at baseline. The percentage of subjects showing a regression of hemorrhage increased from 20% at Day 2 to 64% at Day 15. There was no evidence of an association between the overall hemorrhage regression rate and baseline platelet count.

Approximately half of the 98 subjects in the ITT population had evidence of bleeding at baseline. Post-baseline, the percentage of subjects without bleeding increased to a maximum of 70.4% at Day 8.

REFERENCES

1. Gaines AR. Disseminated intravascular coagulation associated with acute hemoglobinemia or hemoglobinuria following Rh0(D) immune globulin intravenous administration for immune thrombocytopenic purpura. Blood. 2005;106:1532-1537.


2. Pollack W, Ascari WQ, Kochesky RJ, O'Connor RR, Ho TY, Tripodi D. Studies on Rh prophylaxis. 1. relationship between doses of anti-Rh and size of antigenic stimulus. Transfusion. 1971;11:333-339.


3. Thornton JG, Page C, Foote G, Arthur GR, Tovey LAD, Scott JS. Efficacy and long term effects of antenatal prophylaxis with anti-D immunoglobulin. Br Med J. 1989;298:1671-1673.


4. Stucki M, Moudry R, Kempf C, Omar A, Schlegel A, Lerch PG. Characterisation of a chromatographically produced anti-D immunoglobulin product. J Chromatogr B. 1997;700:241-248.


5. Horowitz B, Chin S, Prince AM, Brotman B, Pascual D, Williams B. Preparation and characterization of S/D-FFP, a virus sterilized "fresh frozen plasma". J Thromb Haemost. 1991;65:1163.


6. Horowitz B, Bonomo R, Prince AM, Chin S, Brotman B, Shulman RW. Solvent/detergent-treated plasma: a virus-inactivated substitute for fresh frozen plasma. Blood. 1992;79:826-831.


7. Lazarus AH, Crow AR. Mechanism of action of IVIG and anti-D in ITP. Transfus Apher Sci. 2003;28:249-255.


8. Bichler J, Schöndorfer G, Pabst G, Andresen I. Pharmacokinetics of anti-D IgG in pregnant RhD-negative women. BJOG. 2003;110:39-45.


9. Ware RE, Zimmerman SA. Anti-D: mechanisms of action. Semin Hematol. 1998;35:14-22.


10. MacKenzie IZ, Bichler J, Mason GC, et al. Efficacy and safety of a new, chromatographically purified rhesus (D) immunoglobulin. Eur J Obstetr Gynecol Reprod Biol. 2004;117:154-161.

How Supplied/Storage and Handling

• Rhophylac 1500 IU (300 mcg) is supplied in packages of one or ten (10) prefilled, ready-to-use, glass syringe(s), each containing 2 mL liquid for injection. Each syringe is accompanied by a SafetyGlide™ needle for intravenous or intramuscular use.


• Rhophylac contains no preservatives.


• The prefilled Rhophylac syringe contains no latex.


• DO NOT FREEZE.


• Store at 2 to 8°C (36 to 46°F) for a shelf life of 36 months from the date of manufacture, as indicated by the expiration date printed on the outer carton and syringe label.


• Keep Rhophylac in its original carton to protect it from light.

The following presentations of Rhophylac are available:

NDC Number	Product Description
44206-300-01	1 prefilled 2 mL syringe
44206-300-10	10 prefilled 2 mL syringes

Patient Counseling Information

Both Indications

• Inform patients to immediately report the following signs and symptoms to their physician: hives, chest tightness, wheezing, hypotension, and anaphylaxis.


• Inform patients that Rhophylac is made from human blood and may contain infectious agents that can cause disease (e.g., viruses and, theoretically, the CJD agent). Explain that the risk Rhophylac may transmit an infectious agent has been reduced by screening all plasma donors, by testing the donated plasma for certain viruses, and by inactivating and/or removing certain viruses during manufacturing. Advise patients to report any symptoms that concern them and that may be related to viral infections.


• Inform patients that Rhophylac may interfere with the response to live virus vaccines (e.g., measles, mumps, rubella, and varicella), and instruct them to notify their healthcare professional of this potential interaction when they are receiving vaccinations.

Suppression of Rh Isoimmunization

• Inform patients receiving the antepartum dose of Rhophylac for suppression of Rh isoimmunization that they will need a second dose within 72 hours of birth if the baby's blood type is Rh-positive.

ITP

• Instruct patients being treated with Rhophylac for ITP to immediately report symptoms of intravascular hemolysis, including back pain, shaking chills, fever, discolored urine, decreased urine output, sudden weight gain, edema, and/or shortness of breath.

Manufactured by:

CSL Behring AG

Bern, Switzerland

US License No. 1766

Distributed by:

CSL Behring LLC

Kankakee, IL 60901 USA

Triton™ is a trademark of The Dow Chemical Company

Planova® is a registered trademark of Asahi Kasei Medical Co., Ltd.

SafetyGlide™ is a trademark of Becton, Dickinson and Company

PRINCIPAL DISPLAY PANEL - 300 mcg Syringe Label

Rh0(D) Immune Globulin

Intravenous (Human)

300 mcg

Rhophylac®

1500 IU per 2 mL

For IV or IM Injection. Rx only

CSL Behring AG, Bern, Switzerland

US License No. 1766

Rhophylac® 300 mcg

LOT

Rhophylac® 300 mcg

LOT

LOT

EXP

NDC 44206-300-01

10002552-02/37

PRINCIPAL DISPLAY PANEL - 300 mcg Syringe Carton

NDC 44206-300-01

300 mcg

Rh0(D) Immune Globulin Intravenous (Human)

Rhophylac®

1500 IU

For Intravenous or Intramuscular Injection. Rx only

CSL Behring

Rhophylac  human rho(d) immune globulin  solution

Product Information Product Type HUMAN PRESCRIPTION DRUG NDC Product Code (Source) 44206-300 Route of Administration INTRAVENOUS, INTRAMUSCULAR DEA Schedule

Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength HUMAN RHO(D) IMMUNE GLOBULIN (HUMAN RHO(D) IMMUNE GLOBULIN) HUMAN RHO(D) IMMUNE GLOBULIN 1500 [iU]  in 2 mL

Inactive Ingredients Ingredient Name Strength Albumin (Human) 10 mg  in 1 mL Human Immunoglobulin A   Glycine   Sodium Chloride

Product Characteristics Color      Score      Shape Size Flavor Imprint Code Contains

Packaging # NDC Package Description Multilevel Packaging 1 44206-300-01 1 SYRINGE In 1 CARTON contains a SYRINGE, GLASS 1 2 mL In 1 SYRINGE, GLASS This package is contained within the CARTON (44206-300-01) 2 44206-300-10 10 SYRINGE In 1 CARTON contains a SYRINGE, GLASS 2 2 mL In 1 SYRINGE, GLASS This package is contained within the CARTON (44206-300-10)

Marketing Information
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
BLA	BLA125070	01/06/2009

Labeler - CSL Behring AG (481152762)